News

The Wilms tumor gene (WT1) biomarker is used in the prognosis and follow-up of normal karyotype acute myeloid leukemia (AML) patients, who account for nearly half of AML

Net loss for the 12-month period ended December 31, 2008 was $25.2 million or $1.88 per share, as compared to $13.7 million or $1.09 per share, for the

Dr Hamilton is a recognized expert in both the global development of topically active steroids as well as in graft-versus-host disease (GVHD) and has had a long and

The new US patent, which has 22 claims, includes assessment of heart rate in zebrafish and use of microplates for high-throughput screening. Patricia McGrath, president and CEO of

This was an exploratory human proof of concept efficacy trial to investigate different dosing regimens and routes of administration for Juvidex (Mannose-6-Phosphate) to assess the feasibility of developing

Financial Results IVAX Diagnostics reported loss for the fourth quarter of 2008 was $465,000, compared with net loss of $1,892,000 for the fourth quarter of 2007. Excluding the

Diagnostic Imaging International (DIIG) and Canadian Teleradiology Services (CTS) have entered into an acquisition agreement whereby DIIG acquired all of the outstanding shares of CTS. In conjunction with

According to Meda, the Edluar contains the well-known substance zolpidem and uses Orexo’s patented sublingual tablet formulation. The collaboration agreement with Orexo entitles it to a milestone payment

This first manufacturing unit is set up, according to the European and the FDA guidelines; it allows the production of clinical batches and will allow for the manufacture